Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials

@article{Roustit2013Phosphodiesterase5IF,
  title={Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials},
  author={M. Roustit and S. Blaise and Y. Allanore and P. Carpentier and E. Caglayan and J. Cracowski},
  journal={Annals of the Rheumatic Diseases},
  year={2013},
  volume={72},
  pages={1696 - 1699}
}
Introduction Recent controlled trials have assessed the efficacy of phospodiesterase-5 (PDE-5) inhibitors in secondary Raynaud's phenomenon (RP). However, the conclusions are conflicting, and whether these drugs are effective remains unclear. The objective of this meta-analysis was to determine the efficacy of PDE-5 inhibitors on Raynaud's Condition Score (RCS) and frequency and duration of attacks. Methods A systematic review of articles was performed (sources included Medline, Embase, Web of… Expand
118 Citations

Paper Mentions

Interventional Clinical Trial
The investigators seek to perform a comparative transcriptome analysis of TRP channels residing in the skin between primary and scleroderma secondary Raynaud's phenomenon and… Expand
ConditionsHealthy, Raynaud's Phenomenon Isolated Primary, Raynaud's Phenomenon (Secondary)
InterventionProcedure
Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon
Therapeutic implications from the pathogenesis of Raynaud’s phenomenon
  • A. Herrick
  • Medicine
  • Expert review of clinical immunology
  • 2017
In Raynaud phenomenon, on-demand sildenafil did not reduce disability or frequency or duration of attacks
Treatment options in Raynaud's phenomenon
Drug Treatment of Raynaud’s Phenomenon
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication.
...
1
2
...